BOTHELL, WA and VANCOUVER, Feb. 5, 2013 /CNW/ - OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott
Cormack, President and Chief Executive Officer, will provide a
corporate presentation at the following upcoming investor conferences:
BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 1:00 p.m.
ET at the Waldorf Astoria Hotel in New York City
Leerink Swann Global Healthcare Conference on Wednesday, February 13,
2013 at 2:30 p.m. ET at the Waldorf Astoria Hotel in New York City
RBC Capital Markets Global Healthcare Conference on Tuesday, February
26, 2013 at 11:30 a.m. ET at the New York Palace Hotel in New York City
Live audio webcasts can be accessed through the Investor Relations page
of the OncoGenex website at www.oncogenex.com. Webcast replays will be archived for 60 days.
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries
Ltd. (NYSE: TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and
in patients with advanced, unresectable non-small cell lung cancer.
OGX-427 is in Phase 2 clinical development and OGX-225 is currently in
pre-clinical development. More information is available at www.OncoGenex.com
SOURCE: OncoGenex Pharmaceuticals, Inc.
For further information:
Investor Relations Contact: